LEXINGTON, Mass., June 08, 2016 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective therapeutics for the treatment of cancer, today announced that updated data from the Phase 1 trial of CUDC-907, Curis' proprietary drug candidate in development for treatment of patients with relapsed refractory diffuse large B-cell lymphoma (DLBCL) with MYC gene alterations, will be presented at the 21st Congress of the European Hematology Association to be held from June 9-12 in Copenhagen, Denmark.
Additional information on the presentations can be found below and abstracts can be accessed at www.ehaweb.org.
CUDC-907 Oral Presentation:
| Date/Time: | Saturday, June 11, 2016, 16:45 - 17:00 | ||
| Abstract Number: | S480 | ||
| Presentation Title: | Phase 1 trial of CUDC-907, a novel, oral dual inhibitor of HDAC and PI3K: Updated assessment of patients with relapsed or refractory diffuse large B-cell lymphoma, including double expressor lymphoma | ||
About Curis, Inc.
Curis is a biotechnology company focused on the development and commercialization of innovative drug candidates for the treatment of human cancers, including CUDC-907, which is being investigated in two clinical studies in patients with lymphomas and solid tumors. Curis is also engaged in a broad collaboration with Aurigene in the areas of immuno-oncology and precision oncology. As part of this collaboration, Curis has exercised options to exclusively license oral small molecule antagonists of PD-L1/ VISTA and IRAK4. Curis is also party to a collaboration with Genentech, a member of the Roche Group, under which Genentech and Roche are developing and commercializing Erivedge® for the treatment of advanced basal cell carcinoma. For more information, visit Curis' website at www.curis.com.